NDA 218343 · Amneal
Potassium Phosphates In 0.9% Sodium Chloride
Potassium Phosphate, Dibasic, Potassium Phosphate, Monobasic · Intravenous
Last checked: Nov 20, 2026Latest source record: Jul 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jul 26, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
6 Phase 3, 2 recruiting
FAERS reports
357
301 serious, 64 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 1, 2025.
Potassium Phosphates in Sodium Chloride Injection is indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient, or contraindicated. Potassium Phosphates in Sodium Chloride Injection is a phosphorus replacement product indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient or contraindicated. ( 1 )
Mechanism: Phosphorus in the form of organic and inorganic phosphate has a variety of biochemical functions in all organs and tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE · POTASSIUM PHOSPHATE, DIBASIC 1.18GM/250ML (4.72MG/ML); POTASSIUM PHOSPHATE, MONOBASIC 1.12GM/250ML (4.48MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Potassium Phosphates In 0.9% Sodium Chloride" as an intervention, any sponsor and status, largest first.
- Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05470855 · 45,400 participants (planned) · Start Jul 6, 2022 · Primary completion Nov 30, 2022
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Anqing, China; Chuzhou, China; Fuyang, China · 5 sites in all
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05460429 · 37,920 participants (planned) · Start Jul 30, 2022 · Primary completion Mar 15, 2023
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Chuzhou, China; Lishui, China; Quzhou, China
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldPivotal-lookingCompleted
Shanghai Institute Of Biological ProductsIndustry
NCT05158777 · 2,480 participants · Start Feb 13, 2022 · Primary completion Nov 14, 2022
Drug: Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.; Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd · For: Varicella
Sites: Zhenzhou, China
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldPivotal-lookingStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05015686 · 2,400 participants (planned) · Start Sep 30, 2021 · Primary completion Feb 9, 2022
Drug: Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd; Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd and 2 more · For: Varicella
Sites: Shangqiu, China
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old InfantsPivotal-lookingCompleted
Sinovac Biotech Co., LtdIndustry
NCT05386810 · 1,572 participants · Start Nov 5, 2020 · Primary completion Oct 8, 2022
Drug: Experimental vaccine; IPV control vaccine and 1 more · For: Poliomyelitis
Sites: Kaifeng, China; Xuchang, China
- An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster ImmunizationPivotal-lookingCompleted
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05150392 · 1,193 participants · Start Jul 11, 2018 · Primary completion Aug 11, 2018
Drug: Investigational live attenuated varicella vaccine · For: Varicella
Sites: Kaifeng, China
- Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)Pivotal-lookingCompleted
Jiangsu Rec-Biotechnology Co., Ltd.Industry
NCT05084989 · 948 participants · Start Jan 31, 2022 · Primary completion Aug 18, 2022
Drug: Part1:Recombinant two-component COVID-19 vaccine (CHO cell); Part1: Placebo and 2 more · For: COVID-19
Sites: Roxas City, Philippines
- An Immunity Persistence Study of Live Attenuated Varicella VaccineEnrolling by invitation
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05095701 · 703 participants (planned) · Start Dec 18, 2021 · Primary completion Dec 19, 2021
Drug: Investigational Live Attenuated Varicella Vaccine; Placebo (Freeze Dired Dilution) · For: Varicella
Sites: Xuchang, China; Zhumadian, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea34
- diarrhoea29
- pneumonia25
- vomiting24
- dyspnoea22
- hypotension22
- cytokine release syndrome21
- fatigue18
- febrile neutropenia18
- pyrexia18
- sepsis18
- asthenia16
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 11 |
| 2006 | 23 |
| 2007 | 19 |
| 2008 | 12 |
| 2009 | 29 |
| 2010 | 28 |
| 2011 | 32 |
| 2012 | 22 |
| 2013 | 3 |
| 2015 | 6 |
| 2016 | 8 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 19 |
| 2020 | 23 |
| 2021 | 25 |
| 2022 | 25 |
| 2023 | 22 |
| 2024 | 9 |
| 2025 | 9 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Amneal
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.